## **CLAIMS**:

1. A compound having the formula:

$$R_3$$
 $N(H)$ 
 $NH$ 
 $R_2$ 
 $N(H)$ 
 $R_1$ 

where

$$R_1 = H$$
,  $C_1$ - $C_6$  alkyl, cycloalkyl,  $(CH_2)_n$  or  $(CH_2)_n$   $(n=1-3)$ 

 $R_2 = H$ ,  $C_1$ - $C_6$  alkyl, cycloalkyl

 $W = C_nH_{2n-m}-NH$  (n=1-6, m=0, 2, or 4), -NH or -NH

$$R_3 = R_5$$

$$Y = R_7 N$$
, -CH=CH-,  $R_7 N$ -CH- or -CH-N $R_7$ 

 $Z = CONR_8(CH_2)_n$ ,  $CONR_8(CH_2)_nCO$ ,  $P(CH_3)OCHR_8OCOR_9$ ,  $SO_2$ ,  $SO_2(CH_2)_n$ ,  $SO_2(CH_2)_nCO$ ,  $SO_2NR_8(CH_2)_n$ ,  $SO_2NR_8(CH_2)_nCO$ , n=1-4

 $R_4 = H$ ,  $(CH_2)_nOH$ ,  $(CH_2)_nOCOR_{10}$ ,  $(CH_2)_nNR_{10}R_{11}$ ,  $(CH_2)_nCONR_{10}R_{11}$ , n=0-4

 $R_5 = H_1 (CH_2)_n NR_{12}R_{13}, n = 0-4$ 

 $R_6 = H, (CH_2)_n NR_{14}R_{15}, n = 0-4$ 

 $R_7 = H$ ,  $C_1$ - $C_6$  alkyl, cycloalkyl;  $R_8 = H$ ,  $C_1$ - $C_6$  alkyl, cycloalkyl;  $R_9 = H$ ,  $C_1$ - $C_6$  alkyl, cycloalkyl;  $R_{10} = H$ ,  $C_1$ - $C_6$  alkyl, cycloalkyl;  $R_{11} = H$ ,  $C_1$ - $C_6$  alkyl, cycloalkyl;  $R_{12} = H$ ,  $C_1$ - $C_6$  alkyl, cycloalkyl;  $R_{13} = H$ ,  $C_1$ - $C_6$  alkyl, cycloalkyl;  $R_{14} = H$ ,  $C_1$ - $C_6$  alkyl, cycloalkyl;  $R_{15} = H$ ,  $C_1$ - $C_6$  alkyl, cycloalkyl

(I)

Dashed lines: optional; conformational constraint by  $(CH_2)_n$ , n=1-3, R'=H or O(=)

- 2. A compound according to claim 1 wherein:  $R_1$ ,  $R_2$ =H;  $W = (CH_2)_4$ ; X = -CH(OH)CO-;  $R_5 = H$ ;  $R_6 = 5$ -N(CH<sub>3</sub>)<sub>2</sub>; Y = -CH = CH-; and  $Z = SO_2NHCH_2CO$ .
- 3. A pharmaceutical composition for attenuating the effects of an opiate addiction, opiate dependence, opiate tolerance, opiate related abstinence syndrome, nicotine addiction and obesity comprising said compound of claim 1 in an amount sufficient to effect said attenuation, together with a pharmaceutically acceptable carrier.
- 4. A method of treating an opiate addiction, opiate dependence, opiate tolerance, opiate related abstinence syndrome, nicotine addiction and obesity comprising administering to a mammal in need of such treatment an amount of said compound according to claim 1 sufficient to effect said treatment.
- 15 5. A method of treating an opiate dependence comprising administering to a mammal in need of such treatment an amount of said compound according to claim 1 sufficient to effect said treatment.
- A method of treating an opiate tolerance comprising administering to a mammal in
   need of such treatment an amount of said compound according to claim 1 sufficient to effect said treatment.
  - 7. A method of treating an opiate related abstinence syndrome comprising administering

to a mammal in need of such treatment an amount of said compound according to claim 1 sufficient to effect said treatment.